3-amino-4-dimethylaminothieno[2,3-c]pyridine-2-carboxylic acid methyl ester | 869802-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: 3-amino-4-dimethylaminothieno[2,3-c]pyridine-2-carboxylic acid methyl ester
• 英文别名: 3-amino-4-dimethylamino-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester；Methyl 3-amino-4-(dimethylamino)thieno[2,3-c]pyridine-2-carboxylate
• CAS: 869802-26-6
• 化学式: C₁₁H₁₃N₃O₂S
• 分子量: 251.309
• InChiKey: VNNHYXYDAQHYMB-UHFFFAOYSA-N

物化性质

• 沸点：
  438.2±40.0 °C(Predicted)
• 密度：
  1.362±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  96.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-amino-4-dimethylaminothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 在 对甲苯磺酸 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 32.0h， 生成 9-(dimethylamino)-3-(4-methylphenyl)pyrido[4',3':4,5]thieno[3,2-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  Structure−Activity Relationship of Triazafluorenone Derivatives as Potent and Selective mGluR1 Antagonists

  摘要：

  SAR (structure -activity relationship) studies of triazafluorenone derivatives as potent mGIuR1 antagonists are described. The triazafluorenone derivatives are non-amino acid derivatives and noncompetitive mGluR1 antagonists that bind at a putative allosteric recognition site located within the seven-transmembrane domain of the receptor. These triazafluorenone derivatives are potent, selective, and systemically active mGluR1 antagonists. Compound 1n, for example, was a very potent mGIuR1 antagonist IC50 = 3 nM) and demonstrated full efficacy in various in vivo animal pain models.

  DOI：

  10.1021/jm0504407
• 作为产物：
  描述：

  3,5-二氯-4-氰基吡啶 在 sodium methylate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 3-amino-4-dimethylaminothieno[2,3-c]pyridine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Structure−Activity Relationship of Triazafluorenone Derivatives as Potent and Selective mGluR1 Antagonists

  摘要：

  SAR (structure -activity relationship) studies of triazafluorenone derivatives as potent mGIuR1 antagonists are described. The triazafluorenone derivatives are non-amino acid derivatives and noncompetitive mGluR1 antagonists that bind at a putative allosteric recognition site located within the seven-transmembrane domain of the receptor. These triazafluorenone derivatives are potent, selective, and systemically active mGluR1 antagonists. Compound 1n, for example, was a very potent mGIuR1 antagonist IC50 = 3 nM) and demonstrated full efficacy in various in vivo animal pain models.

  DOI：

  10.1021/jm0504407

文献信息

• Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists
  作者：Guo Zhu Zheng、Pramila Bhatia、Teodozyj Kolasa、Meena Patel、Odile F. El Kouhen、Renjie Chang、Marie E. Uchic、Loan Miller、Scott Baker、Sonya G. Lehto、Prisca Honore、Jill M. Wetter、Kennan C. Marsh、Robert B. Moreland、Jorge D. Brioni、Andrew O. Stewart

  DOI：10.1016/j.bmcl.2006.06.053

  日期：2006.9

  novel, potent, and selective triazafluorenone series of metabotropic glutamate receptor 1 (mGluR1) antagonists with efficacy in various rat pain models. Pharmacokinetic and pharmacodynamic profiles of these triazafluorenone analogs revealed that brain/plasma ratios of these mGluR1 antagonists were important to achieve efficacy in neuropathic pain models. This correlation could be used to guide our in

  我们发现了一种新型，有效和选择性的三氮杂芴酮系列代谢型谷氨酸受体1（mGluR1）拮抗剂，在各种大鼠疼痛模型中均具有功效。这些三氮杂芴酮类似物的药代动力学和药效学特征表明，这些mGluR1拮抗剂的脑/血浆比例对于在神经性疼痛模型中实现疗效很重要。这种相关性可以用来指导我们体内的SAR（结构-活性关系）修饰。例如，化合物4a的脑/血浆比例为0.34，仅在神经性疼痛模型中显示出中等功效。另一方面，脑/血浆比例为2.70的拮抗剂4b在神经性疼痛模型中完全有效。
• [EN] TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS<br/>[FR] COMPOSES TRICYCLIQUES ET LEUR UTILISATION COMME ANTAGONISTES DU MGLUR1
  申请人：SCHERING CORP

  公开号：WO2006002051A1

  公开（公告）日：2006-01-05

  In its many embodiments, the present invention provides tricyclic compounds of Formula (I) (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在其多种实施方式中，本发明提供了式(I)的三环化合物（其中J1-J4，X和R1-R5如本文所定义），作为代谢型谷氨酸受体（mGluR）拮抗剂，特别是选择性代谢型谷氨酸受体1拮抗剂，含有该化合物的制药组合物，以及使用该化合物和组合物治疗与代谢型谷氨酸受体（例如mGluR1）相关的疾病的治疗方法，如疼痛，偏头痛，焦虑，尿失禁和神经退行性疾病，例如阿尔茨海默病。
• mGluR1 Antagonists as therapeutic agents
  申请人：Matasi J. Julius

  公开号：US20060167029A1

  公开（公告）日：2006-07-27

  In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 4 , X, and R 1 -R 5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在许多实施方案中，本发明提供了式 I 的三环化合物（其中 J 1 -J 4 、X 和 R 1 -R 5 如本文所定义）作为代谢型谷氨酸受体（mGluR）拮抗剂，特别是作为选择性代谢型谷氨酸受体 1 拮抗剂，含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗与代谢型谷氨酸受体（如 mGluR1）相关疾病（如疼痛、偏头痛、焦虑、尿失禁和神经退行性疾病，如阿尔茨海默病）的方法。
• WO2006/81072
  申请人：——

  公开号：——

  公开（公告）日：——
• TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS
  申请人：Schering Corporation

  公开号：EP1765829B1

  公开（公告）日：2010-07-07